Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Ospemifene for Vulvar and Vaginal Atrophy in Postmenopausal Women
2007-002372-33Phase 2Completed
- Sponsor
- Hormos Medical
- Start
- May 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ospemifene in vaginal atrophy and menopause (4 arms), sponsored by Hormos Medical. Primary endpoint: Percentage of parabasal cells in the vaginal maturation index. Started May 2007; status: completed.
02
Drugs
ospemifene
03
Conditions
vaginal atrophymenopause
Beyond the preview
Go deeper on 2007-002372-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002372-33.